GRI Bio Inc

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed» Mehr auf globenewswire.com

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled  Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned patients randomized in its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). “We are pleased with the progress made in this Phase 2a biomarker study.» Mehr auf globenewswire.com

LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA. Details of the presentation are as follows: Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis Poster Board Number: 810 Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio Session: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR Date and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PT Location: Room 2022/2024 (West Building, Level 2), Moscone Center For more information about the 2025 ATS International Conference, please visit the conference website, here.» Mehr auf globenewswire.com